L&C BIO Co., Ltd. 290650
KRX · South Korea · Health Technology
KRW 56,300.00+4,500.00 (+8.69%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
L&C Bio stock jumps 12% on plans for an Ozempic fix made from donated human fat, backed by patents in three markets.
As global markets navigate a period of volatility and geopolitical uncertainty, Asian economies are experiencing mixed signals with some regions showing resilience and others facing challenges. Amidst this backdrop, growth companies with high insider ownership can be particularly appealing as they often indicate strong management confidence and alignment with shareholder interests.
L&C Bio (KOSDAQ: 290650, Co-CEOs Hwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue–based regenerative medicine, announced that its premium regenerative solution Re2O (ReCM, ECM: Extra Cellular Matrix) has rapidly emerged as a signature K-Medical tour procedure among international customers within just one year of its launch. Re2O is demonstrating robust sales growth and rapidly expanding its market presence among international visitors to Korea, playing a significant role in the o
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.